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  Diabetes  is  a  metabolic  disorder  which  affects  whole  body  systems  including  reproductive 
system. Diabetes is also a contributing factor to infertility. Metformin is one of the most common 
drugs to control hyperglycemia. In this study, 36 adult Sprague-Dawley female rats (170-210 g) were 
divided into 3 groups (control, diabetic and diabetic-treated by metformin). In second and third 
groups, diabetes was induced by streptozotocin injection (45 mg kg-1, IP) and the third group was 
treated  by  metformin  hydrochloride  (100  mg  kg-1  day-1,  PO)  for  8  weeks.  Body  weights  were 
compared and blood glucose, gonadotropins and sexual hormones were measured. In diabetic group 
the blood glucose level significantly (P < 0.05) increased in comparison with that of control and 
metformin-treated diabetic rats. The results also revealed that, in the untreated diabetic rats, the 
mean body weights and pituitary-gonadal axis hormones were significantly (P < 0.05) reduced in 
comparison with the control. Although there were significant (P < 0.05) reduction in mean body 
weights in metformin-treated diabetic rats, reduction in pituitary-gonadal axis hormones was not as 
sharp  as  in  untreated  diabetic  rats  and  only  level  of  progesterone  was  significantly  (P  <  0.05) 
reduced in comparison with the control. The results of this investigation revealed that there was a 
clear  relationship  between  experimental  diabetes  with  body  weight  and  pituitary-gonadal  axis 
hormones, and treatment with metformin relatively restored diabetic complications. 
© 2012 Urmia University. All rights reserved. 
 Key words:  
 
 Diabetes 
 Metformin 
 Body weight 
 Hormone 
 Rat 
 
 
 
 
 
 
هعلاطم   نزو   ندب   و   حوطس   س֩ولگ   نوخ   و   نومروه   ׌اه   روحم   س׌فوپ׌ه -   دانگ   رد   شوم   ׌اه   ׌׌ارحص   هدام   ׌تبا׌د   و   ׌تبا׌د   نامرد   هدش   اب   ن׌مروفتم  
 هد׌֩چ  
ُا֯تسد ماوت زب ِ֩ تسا ׌֩׌لَباته للاتخا ֩׌ تبا׌د ׌ه زثا ׌لثهذ׌لَت نتس׌س ِلوجسا ىذب ׌اّ ٍراباً رد زثؤه ׌اّرَت֩اف سا ׌֩׌ٍ دراذ֯ لَوعه سا ׌֩׌ ي׌هرَفته .تسا ׌ر  لزتٌ֩ ׌اٍّراد ي׌زت
׌ه ׌وس׌لا֯زپ׌اّ  داذعت ،ِعلاطه ي׌ا رد .ذشاب 36    داضً غلاب ُداه تر زس ֯ازپسا   ׌لٍاد    ׌ًسٍ ُدٍذحه رد 210 - 170   ىاهرد ׌تبا׌د ٍ ׌تبا׌د ،لزتٌ֩( ذًذش ن׌سقت ٍُز֯ ِس ِب ٍ ُذ׌دز֯ ُدافتسا مز֯  اب ُذش
ٍُز֯ رد .)ي׌هرَفته د ׌اّ  ׌قافص لخاد ق׌رشت اب ،مَس ٍ مٍ 45   ِب ذ׌ازلٍ֩رذ׌ٌَّه ي׌هرَفته اب ׌֩ارَخ ىاهرد ،مَس ٍُز֯ رد ٍ ذ׌دز֯ ءاقلا تبا׌د ،ي׌سَتٍسَتپزتسا مزَ֯ل׌֩ زب مز֯ ׌ل׌ه  ىاش׌ه 100  
ِب ٍ سٍر رد مزَ֯ل׌֩ زب مز֯ ׌ل׌ه ىسٍ ،ىا׌اپ رد .ذش ماجًا ِتفّ تشّ تذه َخ شَ֩ل֯ حَطس ٍ ُذ׌دز֯ ِس׌اقه اّ ي׌پٍزتٍداٌ֯ ،ى ىَهرَّ ٍ اّ ُساذًا ׌سٌج ׌اّ  حطس ،׌تبا׌د ٍُز֯ رد .ذًذش ׌ز׌֯
ِب ىَخ شَ֩ل֯ ׌ٌعه رَط ٍُز֯ اب ِس׌اقه رد ׌راد ىاهرد ٍ لزتٌ֩ ׌اّ  دَب ِتفا׌ ش׌اشفا ي׌هرَفته اب ُذش ( 05 / 0   >   P )  . تر رد ،׌فزطسا ىاهرد ׌تبا׌د ׌اّ ىَهرَّ ٍ ىذب ىسٍ طسَته ،ُذشً  رَحه ׌اّ
فَپ׌ّ ش׌ -   ِب لزتٌ֩ ٍُز֯ اب ِس׌اقه رد ،داٌ֯ ׌ٌعه رَط  دَب ِتفا׌ شّا֩ ׌راد ( 05 / 0   >   P )  . ا تر رد ِچز֯ ىاهرد ׌تبا׌د ׌اّ ׌ٌعه شّا֩ ي׌هرَفته اب ُذش  شّا֩ ،تشاد دَجٍ ىذب ىسٍ طسَته رد ׌راد
ىَهرَّ حطس ش׌فَپ׌ّ رَحه ׌اّ -   ِب ،داٌ֯ تر ِتذش ىاهرد ׌اّ ٍزتسصٍزپ حطس طقف ٍ دَبً ،ُذشً ׌ٌعه شّا֩ ى  ׌راد ( 05 / 0   >   P )   ׌ه ىاشً لزتٌ֩ ٍُز֯ ِب تبسً ار  ِ֩ داد ىاشً ׌سرزب ي׌ا ج׌اتً .داد
ه طابترا ׌صخش   ىَهرَّ ٍ ىذب ىسٍ اب ׌بزجت تبا׌د ي׌ب ش׌فَپ׌ّ رَحه ׌اّ -   ِب ،ي׌هرَفته اب ىاهرد ٍ دراد دَجٍ داٌ֯ ׌ه دَبْب ار تبا׌د ضراَع ׌بسً رَط .ذشخب  
:׌د׌ل֩ ׌اه هشاو   با׌د تر ،ىَهرَّ ،ىذب ىسٍ ،ي׌هرَفته ،ت  
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Introduction 
 
Diabetes mellitus is a serious health problem as based 
on  the  World  Health  Organization  (WHO)  report,  the 
number of diabetic patients is expected to increase from 
171 million in year 2000 to 300 million in year 2025 and 
366 million or more by the year 2030.1 Diabetes mellitus 
affects  nearly  every  organ  and  body  system.  Diabetes 
mellitus has adverse effects on sexual function and fertility 
in women, but the effects on women's sexual health have 
received limited attention. Between years 1997 to 2002, 
approximately  1983  articles  has  been  published  on 
diabetes and male sexual dysfunctions, compared to only 
13  articles  published  on  diabetes  and  female  sexual 
dysfunctions. This subject invokes the urgent need for more 
research  in  this  field.2  Some  observations  suggest  an 
association  between  the  reproductive  system,  sex 
hormones,  and  the  development  of  type  I  diabetes  and 
related  end-organ  complications.  However,  very  few 
studies  have  actually  measured  sex  hormone  levels  in 
patients with type I diabetes, their amounts after treatment 
with a drug, correlation between development of diabetes 
with changes in sex hormone levels and its complications.3 
The methylnitrosourea derivative of 2-deoxy-glucose, 
streptozotocin  (STZ),  is  a  valuable  experimental  agent 
used to produce insulin-dependent diabetes in a number 
of animal species, including rat, which is a good lab model 
for experimental diabetes. Streptozotocin is a well-known 
agent for induction of experimental diabetes.4 
Metformin  hydrochloride  is  a  biguanide  that  is  an 
amino group-rich compound like aminoguanidine used in 
treatment of diabetes.5 Metformin is a rather safe drug and 
its  anti-hyperglycemic  property  has  been  generally 
attributed to combination of a decreased rate of intestinal 
absorption of carbohydrate, decreased hepatic gluconeo-
genesis and improvement of peripheral glucose utilization.6 
The aim of this investigation was to evaluate the effects 
of experimental diabetes and treatment with metformin 
on blood glucose levels, pituitary-gonadal axis hormones 
and body weights.  
 
Materials and methods 
 
Animals. Adult Sprague-Dawley female rats weighing 
170-210  g  (10-12  week  old)  were  used  in  this  study. 
Animals  were  obtained  from  Experimental  Animal  Care 
Center, Faculty of Veterinary Medicine, Urmia University 
and  were  maintained  under  standard  conditions  of 
humidity (45%), temperature (22 ± 2 °C) and light (12 h 
light/12 h dark), to gain desired body weight. They were 
fed with a standard rats pellet diet and had free access to 
water. The animals were randomly divided into 3 groups 
consisting  of  12  rats  each;  Group  C:  controls;  Group  D: 
STZ-induced diabetic rats; Group M: STZ-induced diabetic 
rats treated with metformin. 
  Drugs  and  chemicals.  Streptozotocin  (Sigma,  St. 
Louis,  USA.)  was  dissolved  in  freshly  prepared  sodium 
citrate  buffer  0.1M (pH 4.5) and  metformin  HCl (Merck 
Sante S.A.S., Lyon, France) was dissolved in sterile distilled 
water and administered immediately after preparation. 
Induction of diabetes. In groups D and M, diabetes 
was induced by a single intraperitoneal injection of STZ at 
a dosage of 45 mg kg-1 BW in overnight fasting animals. 
This  dosage  of  STZ  has  also  been  employed  by  earlier 
researchers  to  induce  diabetes  in  rats.7  Diabetes  was 
confirmed 48 hours after injection of STZ. The blood of 
fasting animals collected from the tail vein by 24 gauge 
needles  and  glucose  levels  were  determined  with  an 
automated glucose analyzer device (Glucometer, On Call 
EZ, SD, USA). Rats with blood glucose levels more than 200 
mg  dL-1  were  considered  diabetic  and  included  in  the 
study.  Control  animals  were  injected  with  0.1  M  citrate 
buffer, intraperitoneally.  
Treatment  with  metformin.  Oral  treatment  of 
metformin  HCl  (l00  mg  kg-1,  per  day  by  gavage)  was 
started at the 15th day after confirmation of diabetes. The 
treatment was continued for eight weeks (two four-week 
periods). The duration of treatment was based on work of 
others that have used treatment with metformin in four-
week period.8-10 
Body weight and blood collection. At the end of the 
study (71st day after confirmation of diabetes in groups D 
and  M),  the  weight  of  each  overnight  fasting  rat  was 
recorded. Then, they were anesthetized with diethyl ether. 
For measurement of serum glucose levels, gonadotropins 
and sexual hormones the blood was taken through cardiac 
puncture and serum was separated from the blood cells by 
centrifugation. Then, all serum samples were immediately 
stored at -20 °C until further analyses. Serum glucose levels 
were  determined  by  spectrophotometry  using  glucose 
oxidase method (Unico 1200, Japan).  
Serum  gonadotropins  and  sexual  hormones  levels 
were determined with ELISA using specific diagnostic kits 
including  Follicle  Stimulating  Hormone  (FSH)  and 
Luteinizing  Hormone  (LH)  (DRG  Instruments  GmbH, 
Germany); 17-β Estradiol, progesterone, and testosterone 
(Diaplus Inc., USA). Physiological differences in pituitary 
gonadal  hormones  status  happens  in  different  stages  of 
sexual cycle. To obtain confidential results from hormonal 
assays,  we  divided  each  group  into  two  sub-groups:  in 
follicular phase and in luteal phase of ovary; according to 
sex cycle of each rat.11 
 Statistical analysis. The data for various parameters 
(blood  glucose,  body  weight  and  hormones  level)  were 
analyzed using  SAS software,  version 9.1  (SAS.  Institute 
Inc., Cary, NC, USA). All data were reported as mean ± SEM 
and to evaluate significant differences, the comparison of 
means between each two experimental groups was done 
by  Student  t-test  (paired  t-test).  Differences  were 
considered to be statistically significant when P < 0.05. 81  P. Pournaghi et al. Veterinary Research Forum. 2012; 3 (2) 79 - 84 
Results 
 
Symptoms normally associated with the diabetic state 
such as polyuria, polydipsia and polyphagia were seen in 
the diabetic rats (in group D more than group M).  
Effects on fasting blood glucose (FBG). Evaluation of 
serum glucose revealed that there was significant increase 
in both D and M groups compared to that of group C (P < 
0.05). There were also significant differences in levels of 
the parameters (P < 0.05) between groups D and M. The 
highest and lowest serum glucose levels were recorded in 
groups D and C, respectively (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
Fig.  1.  Effect  of  experimental  diabetes  and  treatment  with 
metformin  on  FBG.  *  indicates  significant  difference  at  P  < 
0.05 with group C. † indicates significant difference at P < 0.05 
with group D. 
 
Effects  on  body  weight.  There  was  a  significant 
reduction in mean body weight between group C with D 
and M groups (P < 0.05). However, group M showed a non-
significant reduction in mean body weight as compared to 
group D (Fig. 2). 
 
 
 
 
 
 
 
 
Fig.  2.  Effect  of  experimental  diabetes  and  treatment  with 
metformin on body weight. * indicates significant difference at P < 
0.05 with group C. 
 
Effects  on  gonadotropins.  Mean  ±  SEM  of  FSH 
concentration showed the significant reduction (P < 0.05) 
in  group  D  compared  to  group  C  in  both  follicular  and 
luteal  phases  of  the  ovaries.  But  FSH  concentration  in 
group M displayed no significant difference with groups D 
and  C.  Evaluation  of  LH  concentration  -in  follicular  and 
luteal phases of ovary- showed reduction in both groups D 
and M compared to group C and a reduction in group D 
compared to group M. The differences between all paired 
groups (C&D, C&M and M&D) were significant (P < 0.05). 
These data are displayed on Tables 1 and 2.  
 
  Effects on sexual hormones. As shown in Tables 1 
and  2,  mean  ±  SEM  of  17-β  Estradiol  concentration 
showed  the  significant  reduction  (P  <  0.05)  in  group  D 
compared to group C in both follicular and luteal phases of 
ovary.  But  17-β  Estradiol  concentration  in  group  M 
displayed no significant difference with groups D and C. 
Evaluation of progesterone concentration in follicular and 
luteal  phases  of  ovary  showed  significant  reductions  in 
both D and M groups compared to group C (P < 0.05) and a 
non-significant reduction in group M in comparison with 
group  D.  Total  testosterone  concentrations  in  follicular 
phase of ovary in both groups D and M were significantly 
higher  than  those  of  group  C  (P  <  0.05).  However, 
metformin-treated  diabetic  rats  displayed  a  non-
significant increase in total testosterone concentration in 
comparison with group C in luteal phase of ovary.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
Serum glucose. Increase in serum glucose levels can 
lead to structural and functional changes in target organs 
of diabetic patients.12 In our study, the blood glucose levels 
of  STZ-induced  diabetic  rats  was  significantly  higher. 
These higher blood glucose levels were seen during the 
whole  period  of  study.  The  blood  glucose  levels  in 
untreated diabetics and metformin-treated diabetics were 
significantly higher than those in normal rats in control 
group. Reduction in pancreatic β-cell mass is associated 
with  development  of  diabetes;  streptozotocin  causes 
pancreatic β-cell death and thus reduces the population of 
these  cells.  Effect  of  streptozotocin  on  β-cells  leads  to 
development  of  insufficient  production  of  insulin  and 
consequently, the elevation of blood glucose level occurs.13 
 
Table 1. Effect of experimental diabetes and treatment with metformin on 
blood hormones level in follicular phase of ovary (Mean ± SEM). 
Parameters 
Group C 
(n=5) 
Group D 
(n=5) 
Group M 
(n=4) 
FSH (IU L-1)  0.74 ± 0.03   0.52 ± 0.03*     0.63 ± 0.02 
LH (IU L-1)  0.29 ± 0.00†   0.18 ± 0.00*     0.22 ± 0.01*† 
17-β Estradiol (pg mL-1)  5.62 ± 0.24   3.18 ± 0.18*     3.95 ± 0.11 
Progesterone (ng mL-1)   2.17 ± 0.05   1.42 ± 0.05*     1.37 ± 0.00* 
Testosterone (ng mL-1)  0.17 ± 0.00   0.25 ± 0.00*     0.23 ± 0.00* 
* indicates significant difference at P < 0.05 with group C. 
† indicates significant difference at P < 0.05 with group D. 
 
 
 
 
 
 
Table 2. Effect of experimental diabetes and treatment with metformin on 
blood hormones level in luteal phase of ovary (Mean ± SEM). 
Parameters 
Group C 
(n=7) 
Group D 
(n=7) 
Group M 
(n=8) 
FSH (IU L-1)  0.51 ± 0.02  0.33 ± 0.02*  0.41 ± 0.01 
LH (IU L-1)  0.28 ± 0.01†  0.17 ± 0.00*  0.21 ± 0.00*† 
17-β Estradiol (pg mL-1)  3.01 ± 0.18  1.76 ± 0.08*  2.13 ± 0.05 
Progesterone (ng mL-1)   4.58 ± 0.12  2.88 ± 0.07*  2.71 ± 0.10* 
Testosterone (ng mL-1)  0.19 ± 0.00  0.24 ± 0.00*  0.22 ± 0.00 
* indicates significant difference at P < 0.05 with group C. 
† indicates significant difference at P < 0.05 with group D. 
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In  our  investigation,  there  were  also  significant 
differences  between  blood  glucose  levels  in  untreated 
diabetics  and  metformin-treated  diabetics.  The  blood 
glucose levels in metformin-treated diabetic group were 
lower than untreated diabetic group (P < 0.05). Some of 
the previous studies have reported that metformin exerts 
its glucose-lowering (hypoglycemic) effect by suppressing 
hepatic  glucose  production.14,15  This  drug  reduces 
gluconeogenesis in hepatocytes and amplifies glycogenesis 
and lipogenesis, reduces intestinal absorption of glucose 
and  increases  glucose  intake  in  myocytes  and 
adipocytes.16,17  Metformin  can  reduce  the  resistance  of 
target cells to insulin.18 A mechanism by which metformin 
improves the insulin sensitivity in diabetic patients, may 
be  through  enhancement  in  binding  of  insulin  to  its 
receptors  in  several  cell  types.19  Rossetti  et  al.  have 
reported that metformin treatment of diabetic rats for six 
weeks  leads  to  a  significant  improvement  in  glucose 
tolerance  without any  increase in  insulin secretion.  Our 
data indicated that metformin HCL treatment reduces the 
blood glucose levels in diabetic rats that is in agreement 
with  the  previous  similar  studies.13,19,20  Conversely,  the 
blood glucose lowering effect of metformin is dependent to 
presence of insulin,18 therefore, according to our results it 
seems that an injection of STZ (45 mg kg-1) in rats was not 
able to degenerate all pancreatic β-cells and so did not lead 
to a complete lack of β-cell population. 
Body  weight.  In  our  study,  the  body  weight  of 
untreated diabetic group was reduced significantly. This 
reduction  of  body  weight  was  also  seen  in  metformin-
treated  diabetic  rats as compared to the  normal rats in 
control  groups.  This  data  indicated  that  treatment  of 
diabetic  rats  by  metformin  (100  mg  kg-1  day-1)  had  no 
inhibitory effect on body weight reduction in diabetic rats. 
Our results were in accordance with the results of similar 
previous  studies.13,19,20  Some  studies  reported  that 
treatment of diabetic rats by metformin with dose of 25 
mg  kg-1  caused  more  body  weight  loss  as  compared  to 
non-treated diabetic rats.19 Previous reports have shown 
significant  weight  loss  associated  with  metformin 
treatment in type II diabetes, compared to sulfonylureas or 
placebo.21-23 Weight loss during metformin treatment was 
primarily attributed to loss of adipose tissue and this was 
explained  by  effects  of  different  ways  of  metformin  on 
adipose  tissue  and  muscles.24,25  This  reduction  of  body 
weight  can  be  due  to  breakdown  of  tissue  proteins  in 
diabetic rats.19,26 Metformin can reduce the adipose tissue 
mass  in  the  body.15,18  These  actions  of  metformin  can 
explain the body weight loss in diabetic rats treated with 
metformin  in  comparison  with  untreated  diabetic  and 
control rats in present study. 
Hormones level. In this investigation, the blood 17-β 
Estradiol levels were significantly decreased in untreated 
diabetic group and non-significantly in metformin-treated 
diabetic group in comparison with control group. The 
 
  differences between untreated diabetics and metformin-
treated  diabetics  were  not  significant.  According  to  a 
report, estradiol is associated with diabetes mellitus and 
altered  glucose  tolerance.27  It  has  been  reported  that 
women  with  type  I  diabetes  showed  reduction28  or  no 
change29 in circulating estradiol levels compared to non-
diabetic women. Experimental models of type I diabetes, 
namely  streptozotocin-induced  diabetic  rodents,  have 
shown a more consistent hormonal profile characterized 
by  reduced  estradiol  levels  in  females.30,31  Findings  in 
experimental  models  for  diabetes  are  generally  in 
agreement with the data in humans in that Goto-Kakizaki 
rats exhibit decreased estradiol levels.32 According to the 
present study, metformin treatment of diabetic rats with 
dosage  100  mg  kg-1  body  weight  daily  for  period  of  8 
weeks, could not cause a significant increase in blood 17-β 
Estradiol level. In our study, the total blood testosterone 
levels  in  untreated  diabetic  and  metformin-treated 
diabetic groups significantly increased in comparison with 
control group, whereas this increase of blood testosterone 
levels  was  not  significant  between  these  two  groups. 
Androgens  are  associated  with  diabetes  mellitus  and 
altered glucose tolerance.27 Experimental models of type I  
diabetes, namely streptozotocin-induced diabetic rodents, 
have shown a more consistent hormonal profile which is 
characterized  by  increased  testosterone  levels  in 
females.30,31 Findings in experimental models are generally 
in  agreement  with  the  data  in  humans  in  that  female 
db/db  mice  exhibit  increased  testosterone  levels.33 
Endogenous free testosterone is positively correlated with 
FBG and adiposity.34 Our study indicates that treatment of 
STZ-induced diabetic rats by metformin (100 mg kg-1 body 
weight daily for period of 8 weeks) can decrease the blood 
testosterone  levels  more  in  luteal  phase  than  in  the 
follicular phase of ovary. 
The  results  of  this  investigation  revealed  that 
untreated diabetic group and metformin-treated diabetic 
group had significantly lower blood progesterone levels in 
comparison  with  control  group.  This  indicates  that  the 
experimental  diabetes  cause  reduction  in  progesterone 
level.34 Interestingly the progesterone level in metformin-
treated  diabetic  group  was  less  than  untreated  diabetic 
group,  whereas  LH  level  in  metformin-treated  diabetic 
group is significantly higher than that of untreated diabetic 
group.  Tosca  et  al.  reported  that  metformin-induced 
stimulation  of  adenosine  5'  monophosphate-activated 
protein kinase (PRKA) impaired progesterone secretion in 
rat  granulosa  cells.  According  to  the  present  study, 
metformin treatment of diabetic rats (100 mg kg-1 daily for 
period  of  8  weeks)  cannot  lead  to  increase  in  blood 
progesterone  levels;  moreover  can  decrease  it.  In  this 
study, the assay of blood FSH levels in untreated diabetics 
showed a significant reduction in levels of this hormone 
compared to controls. In experimental diabetes reduction 
in FSH level take place in female rats.35 Also, the blood 
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levels of FSH in metformin-treated diabetic rats was lower 
than that of the control rats. The comparison of blood FSH 
levels between untreated diabetics and metformin-treated 
diabetics showed that the metformin with dosage of 100 
mg kg-1 can improve the blood FSH levels in diabetic rats. 
According to a report, induction of experimental diabetes 
in female rats, leads to reduction in LH level.34 In our study, 
the blood LH levels in untreated diabetic and metformin-
treated diabetic groups was significantly lower than that of 
the control group. Whereas, treatment of diabetic rats with 
metformin caused a significant increase in blood LH levels 
compared  to  group  D,  but  did  not  lead  to  increase  in 
progesterone level and interestingly that caused decrease 
in  progesterone  level.  This  is  in  accordance  with  one 
previous study that was mentioned above.35 Our results 
about  significant  decrease  in  FSH  and  LH  levels  in 
untreated diabetic group compared to control group, are 
in accordance with the results of similar previous study.28 
It  is  concluded  that  there  is  a  direct  relationship 
between experimental diabetes with blood glucose level, 
body  weight  and  pituitary-gonadal  axis  hormones,  and 
treatment with metformin restored diabetic complications. 
This  investigation  needs  to  be  completed  with  other 
studies  in  future  to  find  out  more  about  how  diabetes 
affects female infertility, and preventive and or therapeutic 
measures  should  be  considered  using  drugs  such  as 
metformin  in  reducing  infertility  problems  following 
diabetes in females. 
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